Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-13T05:09:52.672Z Has data issue: false hasContentIssue false
  • English
  • Français

Depression and Parkinson's disease: a conceptual challenge

Published online by Cambridge University Press:  24 June 2014

A. F. G. Leentjens  and
F. R. J. Verhey
A. F. G. Leentjens*
Affiliation:
Department of Psychiatry, Maastricht University Hospital, Maastricht, the Netherlands Institute for Brain and Behavior, Maastricht University, Maastricht, the Netherlands
F. R. J. Verhey
Affiliation:
Department of Psychiatry, Maastricht University Hospital, Maastricht, the Netherlands Institute for Brain and Behavior, Maastricht University, Maastricht, the Netherlands
*
Department of Psyciatry, Maastricht University Hospital, PO Box 5800, 6212 CH Maastricht, the Netherlands. Tel: ++ 31 43 3877443; Fax: + + 31 43 3875444; E-mail: a.leentjens@np.unimaas.nl
Get access Rights & Permissions [Opens in a new window]

Abstract

Aim:

To explore the relation between Parkinson's disease (PD) and depression from a conceptual point of view.

Methods:

Discussion of the relevant literature on the conceptual, phenomenological and therapeutical aspects of depression in Parkinson's disease.

Results:

Both semantic confusion and an erroneous belief in the mind-body distinction have contributed to some common misunderstandings of the nosology and etiology of depression in Parkinson's disease.

Conclusion:

The consequences of a different, integrated, neuropsychiatric approach for both diagnosis and treatment are discussed.

Keywords

cartesian dualismdepressionfunctional psychopathologyParkinson's disease
Type
Review Article
Information
Acta Neuropsychiatrica , Volume 14 , Issue 3 , June 2002 , pp. 147 - 153
Copyright
Copyright © Acta Neuropsychiatrica 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Maty. [quoted in Parkinson, J]. An essay on the shaking palsy. London: Sherwood, Neely and Jones, 1817. Google ScholarPubMed
Todes, C. Inside parkinsonism…a psychiatrist's personal experience. Lancet 1983;i: 977–978. CrossRefGoogle Scholar
Todes, C J. Idiopathic Parkinson's disease and depresison: a psychosomatic view. J Neurol Neurosurg Psychiatry 1984;47: 298–301.CrossRefGoogle Scholar
Hantz, P, Cardoc-Davies, G, Cardoc-Davies, T, Weatherall, M, Dixon, G. Depression in Parkinson's disease. Am J Psychiatry 1994;151: 1010–1014.Google ScholarPubMed
Tandberg, E, Larsen, JP, Aarsland, D, Cummings, JL. The occurrence of depression in Parkinson's disease;a community based study. Arch Neurol 1996;53: 175–179.CrossRefGoogle ScholarPubMed
Cummings, JL. Depression and Parkinson's disease: a review. Am J Psychiatry 1992;149: 443–454.Google ScholarPubMed
Bleuler, E. Manische und depressive Erkrankungen. In: Bleuler, M, ed. Lehrbuch der Psychiatrie. Berlin, Heidelberg, New York: Springer Verlag, 1982: 472–476. Google Scholar
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV-TR). Washington, DC: American Psychiatric Association, 2000. Google ScholarPubMed
Birkmayer, W, Riederer, P. Klinik. Die Parkinson-Krankheit: Biochemie, Klinik, Therapie. Wien, New York: Springer Verlag, 1985: 60–118. CrossRefGoogle Scholar
Van Praag, HM, Asnis, GM, Kahn, RS. Monoamines and abnormal behaviour: a multi-aminergic perspective. Br J Psychiatry 1990;157: 723–734.CrossRefGoogle ScholarPubMed
Hornykiewicz, O. Brain neurotransmitter changes in Parkinson's Disease. In: Marsden, CD, Fahn, S, eds. Movement disorders. London: Butterworths, 1982: 41–58. Google Scholar
Jellinger, K. An overview of morphological changes in Parkinson's disease. Adv Neurol 1986;45: 1–18. Google ScholarPubMed
Scatton, B, Javoy-Agid, F, Rouquier, L, Dubois, B, Agid, Y. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 1983;275: 321–328.CrossRefGoogle ScholarPubMed
Mayeux, R. The ‘serotonergic hypothesis’ for depression in Parkinson's Disease. Adv Neurol 1990;53: 163–166.Google Scholar
Sano, M, Stern, Y, Cote, L, Williams, JB, Mayeux, R. Depression in Parkinson's disease: a biochemical model. J Neuropsychiatr Clin Neurosci 1990;2: 88–92. Google ScholarPubMed
Kostic, VS, Djuricic, BM, Covickovic-Sternic, N, Bumbasirevic, L, Nikoloc, M, Mrsulja, BB. Depression and Parkinson's disease: possible role of serotonergic mechanisms. J Neurol 1987;234: 94–96.CrossRefGoogle Scholar
Kuhn, W, Muler, T, Gerlach, Met al. Depression in Parkinson's Disease. biogenic amines in CSF of ‘de novo’ patients. J Neural Transm 1996;103: 1441–1445.CrossRefGoogle Scholar
Mayeux, R, Stern, Y, Cote, L, Williams, BW. Altered serotonin metabolism in depressed patients with Parkinson's sisease. Neurology 1984;34: 642–646.CrossRefGoogle Scholar
Jacobs, BL, Fornal, CA. 5-HT and motor control: a hypothesis. TINS 1993;16: 346–352.Google ScholarPubMed
Agren, H, Mefford, IN, Rudorfer, MV, Linnoila, M, Potter, WZ. Interacting neurotransmitter systems: a non-experimental appraoch to the 5-HIAA-HVA correlation in human CSF. J Psychiatr Res 1986;20: 175–193.CrossRefGoogle Scholar
Van Praag, HM, De Haen, S. Central serotonergic metabolism and frequency of depression. Psychiatr Res 1979;1: 219–224. CrossRefGoogle Scholar
Fibiger, HC. The neurobiological substrates of depression in Parkinson's disease: a hypothesis. Can J Neurol Sci 1984;11: 105–107.CrossRefGoogle ScholarPubMed
Cantello, R, Aggugia, M, Gilli, Met al. Major depression in Parkinson's disease and the mood response top intravenous methylphenidate: a possible role of the ‘hedonic’ dopamine synapse. J Neurol Neurosurg Psychiatry 1989;52: 724–731.CrossRefGoogle Scholar
Bejjani, BP, Arnulf, I, Thivard, Let al. Transient acute depression by high-frequency deep-brain stimulation. N Engl J Med 1999;340: 1476–1480.CrossRefGoogle ScholarPubMed
Portman, AT, Leenders, KL, Van Laar, T, Staal, MJ, Journee, HL, Den Dunnen, WFA. Depressie na chronische subthalamicusstimulatie bij de ziekte van Parkinson. Ned Tijdschr Neurol 2001;2: 108–111. Google Scholar
Krack, P, Kumar, R, Ardouin, Cet al. Mirthful laughter induced by subthalamic nucleus stimulation. Mov Dis 2001;16: 867–875. CrossRefGoogle ScholarPubMed
Yudofsky, S. Parkinson's disease, depression, and electrical stimulation of the brain. N Engl J Med 1999;340: 1500–1502.CrossRefGoogle ScholarPubMed
Rampello, L, Nicoletti, G, Raffaele, R. Dopaminergic hypothesis for depression: a symptom profile for predicting therapeutical responses. Acta Psychiatr Scand 1991;84: 552–554.CrossRefGoogle Scholar
Van Praag, HM. Depression. Lancet 1982;ii: 1259–1264. CrossRefGoogle Scholar
Brown, R, Jahanshahi, M. Depression in Parkinson's disease: a psychosocial viewpoint. In: Weiner, J, Lang, AE, eds. Behavioral neurology of movement disorders: Adv Neurol, vol. 65. New York: Raven Press 1995: 61–84. Google Scholar
Birkmayer, W, Birkmayer, JD. Dopamine action and disorders of neurotransmitter balance. Gerontology 1987 1980;33: 168–171.CrossRefGoogle ScholarPubMed
Riederer, P, Birkmayer, WA. New concept: brain area specific imbalance of neurotransmitters in depression syndrome: human brain studies. In: Usdin, E, Sourkes, TL, Youdim, MBH, eds. Enzymes and neurotransmitters in mental disease. New York: John Wiley and Sons Ltd, 1980; 261–279. Google Scholar
Rosenstein, DL. More in the depressive effects of interferon alfa. N Engl J Med 1999;341: 849–850.Google ScholarPubMed
Honig, A, Lousberg, R, Wojciechowski, FL, Cheriex, EC, Wellens, HJ, Van Praag, HM. Depressie na een eerste myocardinfarct: overeenkomsten en verschillen met ‘depressie’. Nederl Tijdschr Geneesk 1997;141: 196–199. Google Scholar
Gotham, AM, Brown, RG, Marsden, CD. Depression in Parkinson's disease, a quantitative and qualitative approach. J Neurol Neurosurg Psychiatry 1986;49: 381–389.CrossRefGoogle Scholar
Ehmann, TS, Beninger, RJ, Gawel, MJ, Riopelle, RJ. Depressive symptoms in Parkinson's disease: a comparison with disabled control subjects. J Geriatr Psychiatr Neurol 1990;3: 3–9. Google Scholar
Huber, SJ, Freidenberg, DL, Paulson, GW, Shuttleworth, CJA. The pattern of depressive symptoms varies with progression of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53: 257–258. CrossRefGoogle Scholar
Taylor, RE. Death of neurasthenia and its psychological reincarnation: a study of neurasthenia at the National Hospital for the Relief and Cure of the Paralysed and Epileptic, Queen Square, London, 1870–1932. Br J Psychiatry 2002;179: 550–557. CrossRefGoogle Scholar
Kandel, ER. A new intellectuel framework for psychiatry. Am J Psychiatry 1998;155: 457–470.CrossRefGoogle Scholar
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-III). Washington: American Psychiatric Association, 1980. Google ScholarPubMed
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-III-R). Washington: American Psychiatric Association, 1987. Google Scholar
American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorder. Washington, DC: American Psychiatric Association, 2000: 413–495. Google Scholar
Klaassen, T, Verhey, FRJ, Sneijders, GHJM, Rozendaal, N, De Veth, HCW, Van Praag, HM. Treatment of depression in Parkinson's disease: a meta-analysis. J Neuropsychiatr Clin Neurosci 1995;7: 281–286. Google ScholarPubMed
Schwartz, JM, Stoessel, PW, Baxter, LR, Martin, KM, Phelps, ME. Systematic changes in cerebral glucose metabolic rate after succesfull behavior modification treatment of obsessive-compulsive disorders. Arch Gen Psychiatry 1996;53: 109–113.CrossRefGoogle Scholar
Brody, AL, Saxena, S, Stoessel, Pet al. Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy. Arch Gen Psychiatry 2001;58: 631–640.CrossRefGoogle Scholar
Malone, KM, Thase, ME, Mieczkowski, Tet al. Fenfluramine challenge test as a predictor of outcome in major depression. Psychopharmacol Bull 1993;29: 155–161.Google Scholar
Leo, RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 1996;57: 449–454.CrossRefGoogle ScholarPubMed
Poewe, W, Luginger, E. Depression in Parkinson's disease. impediments to recognition and treatment options. Neurology 1999;52 (Suppl. 3):S2–S6.Google ScholarPubMed
Huszonek, JJ. Anticholinergic effects in a depressed parkinsonian patient. J Geriatr Psychiatr Neurol 1995;8: 100–102. CrossRefGoogle Scholar
Factor, SA, Molho, ES, Podskalny, GD, Brown, D. Parkinson's disease: drug-induced states. In: Weiner, WJ, Lang, AE, eds. Behavioral neurology of movement disorders: Adv in Neurol, vol. 65. New York: Raven Press Ltd, 1995; 115–138. Google Scholar
Gerber, PE, Lynd, LD. Selective serotonin-reuptake inhibitor-induces movement disorders. Ann Pharmacother 1998;32: 692–698.CrossRefGoogle ScholarPubMed
Friedman, JH, Factor, SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Dis 2000;15: 201–211. 3.0.CO;2-D>CrossRefGoogle ScholarPubMed